CLAIMS

1. A pharmaceutical composition comprising an erythropoietin to which two or more straight-chain polyethylene glycol are added, wherein an amount of said erythropoietin is not less than 50% of total erythropoietin, and wherein the erythropoietin is the following (a) to (c):

(a) a polypeptide having an amino acid sequence set forth in SEQ ID NO:1;

(b) a polypeptide that has an amino acid sequence of not less than 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:1, and has an erythropoietin activity in a cell proliferation assay using BaF/EPOR cells; or

(c) a polypeptide that has one or a plurality of amino acid substitutions, deletions, insertions and/or additions with respect to the amino acid sequence set forth in SEQ ID NO:1, and has an erythropoietin activity in a cell proliferation assay using BaF/EPOR cells.

2. The pharmaceutical composition according to claim 1, wherein the subject of administration is an animalof the family Felidae and/or the family Canidae.

3. The pharmaceutical composition according to claims 1 or 2, which has a hematopoietic effect in an animal of the family Felidae and/or the family Canidae which lasts for not less than seven days.

4. The pharmaceutical composition according to any one of claims 1 to 3, which is a solution or gel having a pH of not less than 4 but not more than 8.

5. The pharmaceutical composition according to any one of claims 1 to 4, wherein not less than one polyethylene glycol addition site is a lysine-78 residue.

6. The pharmaceutical composition according to any one of claims 1 to 5, wherein even when repeatedly administered, the pharmaceutical composition does not trigger the production of an antibody to erythropoietin.

7. A drug for treating anemia, comprising the pharmaceutical composition according to any one of claims 1 to 6.

8. A hematopoietic drug, comprising the pharmaceutical composition according to any one of claims 1 to 6.

CLAIMS

1. A pharmaceutical composition comprising an erythropoietin to which two or more straight-chain polyethylene glycol are added, wherein an amount of said erythropoietin is not less than 50% of total erythropoietin, and wherein the erythropoietin is the following (a) to (c):

(a) a polypeptide having an amino acid sequence set forth in SEQ ID NO:1;

(b) a polypeptide that has an amino acid sequence of not less than 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:1, and has an erythropoietin activity in a cell proliferation assay using BaF/EPOR cells; or

(c) a polypeptide that has not more than 30 amino acid substitutions, deletions, insertions and/or additions with respect to the amino acid sequence set forth in SEQ ID NO:1, and has an erythropoietin activity in a cell proliferation assay using BaF/EPOR cells.

2. The pharmaceutical composition according to claim 1, wherein the subject of administration is an animal of the family Felidae.

3. The pharmaceutical composition according to any one of claim 1 or 2, which is a solution or gel having a pH of not less than 4 but not more than 8.

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein not less than one polyethylene glycol addition site is a lysine-78 residue.

5. A drug for treating anemia, comprising the pharmaceutical composition according to any one of claims 1 to 4.

6. A hematopoietic drug, comprising the pharmaceutical composition according to any one of claims 1 to 4.